New! Sign up for our free email newsletter.
Science News
from research organizations

Activation of two genes linked to development of atherosclerosis

Date:
October 28, 2016
Source:
Brigham and Women's Hospital
Summary:
Two new potential drug targets for treating arterial diseases such as atherosclerosis have been identified by researchers. By using proteomics to screen a vast number of molecules, the researchers identified PARP9 and PARP14 - two members of the PARP family of proteins - as regulators of macrophage activation, which has been linked to arterial disease by systems biology.
Share:
FULL STORY

Researchers at Brigham and Women's Hospital have found two new potential drug targets for treating arterial diseases such as atherosclerosis. By using proteomics to screen a vast number of molecules, the researchers identified PARP9 and PARP14 -- two members of the PARP family of proteins -- as regulators of macrophage activation, which has been linked to arterial disease by systems biology.

Though the mechanisms that activate macrophages, a type of digestive white blood cell that targets foreign cells, remain incompletely understood, previous research shows that macrophages play an important role in the development of atherosclerosis and its thrombotic complications. Masanori Aikawa, MD, PhD, director of the Center for Interdisciplinary Cardiovascular Sciences (CICS) at the Brigham, his research fellow Hiroshi Iwata, MD, PhD, and colleagues studied atherosclerosis on the protein-level to determine which molecules were most involved in the regulation of macrophages.

Once Aikawa and his colleagues narrowed down their search to these two proteins, they silenced each gene in cultured macrophages and found that tamping down PARP14 increased macrophage activation while tamping down PARP9 had the opposite effect.

Aikawa founded CICS and hopes that this hypothesis-generating method can be used to streamline the lengthy process of drug development. Aikawa and CICS are using a more systematic approach which hinges on network analysis; this analysis predicts which pathways are most likely to control their studied effect so that they can prioritize these pathways. Ideally, this process would take a fraction of the time in comparison to searching through each individual pathway unaware of their likelihood of affecting their studied effect.

Aikawa and his colleagues plan to augment these findings to develop targeted therapeutics for atherosclerosis and other diseases.

"Macrophage activation plays a role in not only vascular disorders but also various inflammatory and autoimmune diseases," said Aikawa. "These results could provide important information about the mechanisms of these diseases and help to develop much needed new therapeutics."


Story Source:

Materials provided by Brigham and Women's Hospital. Note: Content may be edited for style and length.


Journal Reference:

  1. Hiroshi Iwata, Claudia Goettsch, Amitabh Sharma, Piero Ricchiuto, Wilson Wen Bin Goh, Arda Halu, Iwao Yamada, Hideo Yoshida, Takuya Hara, Mei Wei, Noriyuki Inoue, Daiju Fukuda, Alexander Mojcher, Peter C. Mattson, Albert-László Barabási, Mark Boothby, Elena Aikawa, Sasha A. Singh, Masanori Aikawa. PARP9 and PARP14 cross-regulate macrophage activation via STAT1 ADP-ribosylation. Nature Communications, 2016; 7: 12849 DOI: 10.1038/NCOMMS12849

Cite This Page:

Brigham and Women's Hospital. "Activation of two genes linked to development of atherosclerosis." ScienceDaily. ScienceDaily, 28 October 2016. <www.sciencedaily.com/releases/2016/10/161028113724.htm>.
Brigham and Women's Hospital. (2016, October 28). Activation of two genes linked to development of atherosclerosis. ScienceDaily. Retrieved April 26, 2024 from www.sciencedaily.com/releases/2016/10/161028113724.htm
Brigham and Women's Hospital. "Activation of two genes linked to development of atherosclerosis." ScienceDaily. www.sciencedaily.com/releases/2016/10/161028113724.htm (accessed April 26, 2024).

Explore More

from ScienceDaily

RELATED STORIES